Floatz logo

LEUPROLIDE

Unresectable Solid Tumor

Relay Therapeutics, Inc.protein_peptidePhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Unresectable Solid Tumor cohort.

Asset / SponsorPhaseRating
[177lu]lu-sn201
Spago Nanomedical AB
Phase 1/2CC
Mdna11
Medicenna Therapeutics, Inc.
Phase 1/2CC
Fmc-376
Frontier Medicines Corporation
Phase 1/2CC
Pembrolizumab
Medicenna Therapeutics, Inc.
Phase 1/2CC
FULVESTRANT
Relay Therapeutics, Inc.
Phase 1CC

View all 20 →

Same molecule, other indications

LEUPROLIDE is also rated in:

prostate carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
metastatic prostate carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →